文献速递真菌感染

瑞扎芬净(CD101)对曲霉属(包括耐唑类烟曲霉分离株和隐蔽种)显示出强效体外活性

Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

瑞扎芬净是一种在研棘白菌素,本研究采用CLSI M38-A2微量肉汤稀释法检测其对多种曲霉临床分离株的体外活性,包括15株野生型和31株耐唑类烟曲霉及隐蔽种。瑞扎芬净对野生型和耐唑类烟曲霉的几何平均MEC分别为0.024和0.043 mg/L,对隐蔽种也有活性,对A. calidoustus的活性强于卡泊芬净(GM MEC 0.044 vs 0.468 mg/L,P < 0.0001)。结论认为其体外活性强,但需进一步研究以确定体外活性是否能转化为体内疗效。

要点

  • 瑞扎芬净对野生型和耐唑类烟曲霉的GM MEC分别为0.024和0.043 mg/L。
  • 对A. calidoustus,瑞扎芬净GM MEC 0.044 mg/L,低于卡泊芬净的0.468 mg/L(P < 0.0001)。
  • 对A. lentulus、A. thermomutatus和A. udagawae等隐蔽种也显示体外活性。

核心结论

  • 瑞扎芬净对曲霉属(包括耐唑类烟曲霉和隐蔽种)显示出强效体外活性。
  • 需进一步研究以确定体外活性是否能转化为对耐药曲霉感染的体内疗效。

研究设计与样本

  • 研究采用曲霉临床分离株:15株野生型和31株耐唑类烟曲霉、11株A. lentulus、A. thermomutatus和A. udagawae各5株、11株A. calidoustus。
  • 通过CLSI M38-A2微量肉汤稀释法测定瑞扎芬净、卡泊芬净、米卡芬净、泊沙康唑和伏立康唑的最低有效浓度(MEC)和MIC。
  • 采用ANOVA评估几何平均(GM)MEC/MIC值差异的显著性。

主要发现

  • 瑞扎芬净对野生型和耐唑类烟曲霉的GM MEC分别为0.024和0.043 mg/L。
  • 瑞扎芬净对A. lentulus的GM MEC为0.016 mg/L,对A. calidoustus为0.044 mg/L。
  • 瑞扎芬净对A. thermomutatus的MEC范围为≤0.015-0.25 mg/L,对A. udagawae为≤0.015-0.03 mg/L。
  • 对A. calidoustus,瑞扎芬净GM MEC 0.044 mg/L vs 卡泊芬净0.468 mg/L(P < 0.0001)。
  • 除A. calidoustus外,瑞扎芬净活性与卡泊芬净和米卡芬净相似。

关键数值与推荐

  • 瑞扎芬净对野生型烟曲霉GM MEC 0.024 mg/L,对耐唑类烟曲霉GM MEC 0.043 mg/L。
  • 瑞扎芬净对A. lentulus GM MEC 0.016 mg/L,对A. calidoustus GM MEC 0.044 mg/L。
  • 瑞扎芬净对A. thermomutatus MEC范围≤0.015-0.25 mg/L,对A. udagawae MEC范围≤0.015-0.03 mg/L。
  • 对A. calidoustus,瑞扎芬净GM MEC 0.044 mg/L vs 卡泊芬净0.468 mg/L(P < 0.0001)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为需进一步研究以确定体外活性是否能转化为体内疗效。

局限性

  • 需进一步研究以确定体外活性是否能转化为对耐药曲霉感染的体内疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rezafungin is an investigational echinocandin under development for the treatment and prevention of invasive fungal infections, with a long half-life in humans (∼130 h) and potent in vitro activity against Aspergillus spp. Our objective was to further evaluate its activity against Aspergillus fumigatus isolates, including azole-resistant isolates and cryptic Aspergillus spp. METHODS: Clinical isolates of Aspergillus were used, including 15 WT and 31 azole-resistant A. fumigatus, 11 Aspergillus lentulus, 5 each of Aspergillus thermomutatus and Aspergillus udagawae and 11 Aspergillus calidoustus. Minimum effective concentrations (MECs) and MICs of rezafungin, caspofungin, micafungin, posaconazole and voriconazole were determined by CLSI M38-A2 broth microdilution. Differences in geometric mean (GM) MEC/MIC values were assessed for significance by ANOVA. RESULTS: Rezafungin GM MECs for A. fumigatus were 0.024 and 0.043 mg/L for WT and azole-resistant isolates, respectively. Rezafungin was also active against cryptic species, including A. lentulus (0.016 mg/L), A. calidoustus (0.044 mg/L), A. thermomutatus (MEC range ≤0.015-0.25 mg/L) and A. udagawae (≤0.015-0.03 mg/L). This activity was similar to that of caspofungin and micafungin with the exception of A. calidoustus, against which rezafungin was more potent than caspofungin (GM MEC 0.044 versus 0.468 mg/L; P < 0.0001). CONCLUSIONS: Rezafungin demonstrated potent in vitro activity against Aspergillus spp., including azole-resistant A. fumigatus isolates and cryptic species with elevated posaconazole and voriconazole MICs. Additional studies are warranted to determine whether the in vitro activity translates into in vivo efficacy against infections caused by resistant Aspergillus isolates.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wiederhold NP, Locke JB, Daruwala P, et al. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. J Antimicrob Chemother. 2018. PMID: 30032217. doi:10.1093/jac/dky280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。